AmVac AG (Zug, Switzerland) has formed a collaboration with the National Health Research Institutes in Taiwan to develop a nasal spray vaccine against the H5N1 avian influenza.
AmVac AG (Zug, Switzerland) has formed a collaboration with the National Health Research Institutes in Taiwan to develop a nasal spray vaccine against the H5N1 avian influenza.
The vaccine will use AmVac’s adjuvant, MALP-2, which is suitable for absorption through mucosal membranes.
Up to now, the development of a flu vaccine spray has been hampered by the lack of a safe adjuvant capable of enhancing strong mucosal immunity. AmVac has acquired exclusive rights to the adjuvant MALP-2 (Macrophage Activating Lipopeptide-2), developed by C. Guzman at the Helmholtz Center for Infection Research in Braunschweig, for all infectious diseases worldwide. This synthetic, well-tolerated class of adjuvants acts as a toll-like receptor agonist in activating cells of the immune system and thus at central sites in mediation of the immune response. Preliminary results in mice have revealed that the pandemic H5N1 flu vaccine combined with MALP-2 elicits flu-specific antibodies following intranasal immunization.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.